201 related articles for article (PubMed ID: 23086460)
1. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
Pasha FA; Neaz MM
J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
[TBL] [Abstract][Full Text] [Related]
2. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.
Tripathi SK; Singh SK
Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777
[TBL] [Abstract][Full Text] [Related]
3. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
7. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
8. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach.
Tripathi SK; Soundarya RN; Singh P; Singh SK
Chem Biol Drug Des; 2015 Feb; 85(2):107-18. PubMed ID: 24923208
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
Ai Y; Wang ST; Sun PH; Song FJ
Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.
Rath SL; Senapati S
PLoS One; 2013; 8(9):e73836. PubMed ID: 24058495
[TBL] [Abstract][Full Text] [Related]
12. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
13. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
14. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
15. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
Dessalew N; Singh SK
Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
[TBL] [Abstract][Full Text] [Related]
17. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
18. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.
Alzate-Morales JH; Contreras R; Soriano A; Tuñon I; Silla E
Biophys J; 2007 Jan; 92(2):430-9. PubMed ID: 17085505
[TBL] [Abstract][Full Text] [Related]
19. Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines.
Brahmkshatriya PS; Dobeš P; Fanfrlik J; Rezáç J; Paruch K; Bronowska A; Lepšík M; Hobza P
Curr Comput Aided Drug Des; 2013 Mar; 9(1):118-29. PubMed ID: 23157414
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors.
Araki M; Kamiya N; Sato M; Nakatsui M; Hirokawa T; Okuno Y
J Chem Inf Model; 2016 Dec; 56(12):2445-2456. PubMed ID: 28024406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]